Global Deferasirox Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Deferasirox Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta- thalassemia and other chronic anemias.
Deferasirox is marketed as Exjade, Desirox, Defrijet, Desifer, and Jadenu.
The half-life of deferasirox is between 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to 1 atom of iron which is subsequently eliminated by fecal excretion. Its low molecular weight and high lipophilicity allows the drug to be taken orally unlike deferoxamine which has to be administered by IV route (intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron from cells (cardiac myocytes and hepatocytes) as well as removing iron from the blood.
Deferasirox report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Deferasirox market is projected to reach US$ 3728.5 million in 2034, increasing from US$ 2729.8 million in 2022, with the CAGR of 4.5% during the period of 2024 to 2034. Demand from Transfusional Iron Overload and NTDT Caused Iron Overload are the major drivers for the industry.
The major global manufacturers of Dillaros are Novartis, Cipla, Natco Pharma and Sun Pharma, among which Novartis is the industry leader with a market share of around 99%. North America is the largest spending region, with 30 per cent of the market, followed by Europe with 25 per cent.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Deferasirox market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Novartis
Cipla
Natco Pharma
Sun Pharma
Segment by Type
500 mg/Tablet
250 mg/Tablet
125 mg/Tablet
Others
Transfusional Iron Overload
NTDT Caused Iron Overload
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Deferasirox market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Deferasirox, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Deferasirox industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Deferasirox in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Deferasirox introduction, etc. Deferasirox Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Deferasirox market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Deferasirox is marketed as Exjade, Desirox, Defrijet, Desifer, and Jadenu.
The half-life of deferasirox is between 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to 1 atom of iron which is subsequently eliminated by fecal excretion. Its low molecular weight and high lipophilicity allows the drug to be taken orally unlike deferoxamine which has to be administered by IV route (intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron from cells (cardiac myocytes and hepatocytes) as well as removing iron from the blood.
Deferasirox report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Deferasirox market is projected to reach US$ 3728.5 million in 2034, increasing from US$ 2729.8 million in 2022, with the CAGR of 4.5% during the period of 2024 to 2034. Demand from Transfusional Iron Overload and NTDT Caused Iron Overload are the major drivers for the industry.
The major global manufacturers of Dillaros are Novartis, Cipla, Natco Pharma and Sun Pharma, among which Novartis is the industry leader with a market share of around 99%. North America is the largest spending region, with 30 per cent of the market, followed by Europe with 25 per cent.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Deferasirox market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Novartis
Cipla
Natco Pharma
Sun Pharma
Segment by Type
500 mg/Tablet
250 mg/Tablet
125 mg/Tablet
Others
Segment by Application
Transfusional Iron Overload
NTDT Caused Iron Overload
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Deferasirox market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Deferasirox, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Deferasirox industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Deferasirox in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Deferasirox introduction, etc. Deferasirox Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Deferasirox market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices